Norastemizole Sepracor

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 219-226

  Bachmann, K A ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CAREBASTINE; CETIRIZINE; CYTOCHROME P450 3A4; DESLORATADINE; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE; ITRACONAZOLE; KETOCONAZOLE; LEVOCETIRAZINE; LORATADINE; NORASTEMIZOLE; TERFENADINE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ALLERGY; BRONCHOSPASM; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; EXPERIMENTAL MODEL; HEADACHE; HEART ARRHYTHMIA; HUMAN; NONHUMAN; QT INTERVAL; REVIEW; RHINITIS; SEDATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; PIPERIDINES; RHINITIS, ALLERGIC, SEASONAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033765783     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Identification of the disulfide bond pattern in albolabrin, an RGD-containing peptide from the venom of Trimeresurus albolabris: Significance for the expression of platelet aggregation inhibitory activity
2. 1 antihistamines
3. Sepracor files IND to initiate clinical trials on norastemizole improved allergy drug
4. Antiallergic effects of major metabolites of astemizole in rats and guinea pigs
5. Spectrophotometric quantification of astemizole and its demethylated metabolite in urine after TLC separation
6. Pharmacokinetics of astemizole in children
7. Astemizole: General pharmacological activities of major metabolites
8. General pharmacology of Astemizole and its 3 main metabolites (desmethyl-, 6-hydroxydesmethyl- and nor-astemizole)
9. Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man
10. Radioimmunoassay procedures for astemizole and metabolites in plasma
11. Pharmacokinetics and tissue distribution of astemizole in the dog
12. Excretion and biotransformation of astemizole in rats, guinea pigs, dogs and man
13. Simultaneous determination of astemizole and its demethylated metabolite in animal plasma and tissues by high-performance liquid chromatography
14. Interim results support continuation of Phase III clinical trial for Xoma's E5® product
15. R-salbutamol ready for Phase III
16. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects
17. Annual Report 1995 - Sepracor Inc
18. Sepracor - SmithBarney analyst report December 1995
19. Sepracor announces third quarter 1996 financial results
20. Sepracor initiates pediatric asthma trial
21. Sepracor presents positive data from antihistamine trials
22. Torsade de pointes with an antihistamine metabolite: Potassium channel blockade with desmethylastemizole
23. Sepracor presents at Hambrecht and Quist Conference/Company outlines product development milestones and marketing strategy
24. Sepracor presents data at Georgetown center for drug development conference
25. The Annual meeting of the American College of Allergy, Asthma and Immunology Boston, USA
26. Sepracor's product launch timetable
27. Sepracor's revenues down 7% in 1996
28. Sepracor announces 1996 financial results
29. Sepracor's norastemizole shows excellent potency, safety and rapid onset of action
30. Clinical trials update
31. Sepracor announces first quarter 1997 financial results
32. Annual Report 1996 - Sepracor Inc
33. Sepracor Fact Sheet - Improving safety and efficacy of best-selling pharmaceuticals
34. Allergy drug candidate moving into pivotal phase IVIII hay fever study
35. Sepracor's progress with norastemizole
36. Effects of the anti-allergics astemizole and norastemizole on Fc ε RI receptor-mediated signal transduction processes
37. 1-antihistaminic norastemizole
38. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole
39. A study of the interaction between dirithromycin and astemizole in healthy adults
40. Astemizole (Hismanal by Jansen) - A non-sedating, long-acting antihistamine
41. Effects of magnesium sulfate on the canine cardiovascular system complicating astemizole overdose
42. Norastemizole/Claritin(Loratidine)
43. Sepracor goes ahead with salesforce plan
44. New US co-marketer and indication for Penederm's Mentax
45. A parallel-group comparison of astemizole and loratadine for the treatment of perennial allergic rhinitis
46. US Posicor warnings stricter than EC's
47. Effects of chlorpheniramine, pyrilamine and astemizole on intracranial self-stimulation in rats
48. 1 antagonist, astemizole
49. Sepracor announces collaboration with Janssen for worldwide development and marketing of norastemizole
50. Sepracor/Janssen deal on norastemizole
51. Stronger US warnings for J and J's Hismanal
52. 1-adrenoceptor subtypes on the rat prostate
53. Norastemizole does not affect ECG parameters
54. Effects of varying doses of norastemizole on histamine induced wheal (W) and flare (F) responses and ECG
55. Sepracor announces completion of norastemizole trial
56. Latest progress with levalbuterol
57. Therapeutic advantages of third generation antihistamines
58. Sepracor announces third quarter 1998 financial results
59. Merrill Lynch: Pharmaceutical and Biotechnology Bulletin
60. Sepracor announces 1998 financial results
61. Morgan Stanley Dean Witter: US Investment Research: Johnson and Johnson
62. J and J elects not to exercise option to copromote norastemizole Sepracor to complete development and market product
63. Merrill Lynch: Pharmaceutical Biotechnology and Medical Device Bulletin
64. Hismanal withdrawal will allow Sepracor to define metabolite as new drug
65. Morgan Stanley Dean Witter: Johnson and Johnson
66. Sepracor announces second quarter 1999 financial results
67. Sepracor norastemizole onset of action claim to be based on chamber data
68. James O'Shea former Zeneca executive joins Sepracor as President and Chief Operating Officer
69. Medical Aspects of Drug Safety and Pharmacovigilance, London, UK
70. Annual Report 1998 - Sepracor Inc
71. Palladium catalysis in the synthesis of medicinal agents
72. Merrill Lynch: Global Healthcare Bulletin - Merrill Lynch's Global Pharmaceutical, Medical Technology and Products, and Biotechnology Conference, New York City
73. Descarboethoxyloratadine, a metabolite of loratadine, is a superior antihistamine
74. Merrill Lynch: Global healthcare bulletin
75. American Academy of Allergy, Asthma and Immunology - 56th Annual Meeting (Part II) San Diego, CA, USA
76. Allergic rhinitis: Basic pathophysiology and therapeutic strategies
77. Annual Report 1999 - Sepracor Inc
78. Johnson and Johnson
79. Chiral switches
80. Les effets secondaires cardiovasculaires des anti-H
81. Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
82. American Academy of Asthma, Allergy and Immunology - 56th annual meeting: 3-8 March 2000, San Diego, CA, USA
83. Desloratadine Sepracor
84. Cardiotoxic potential and CNS effects of first-generation antihistamines
85. The metabolic profile of second-generation antihistamines
86. Properly tuned first fluoride-catalyzed TGME-mediated amination process for chloroimidazoles: Inexpensive technology for antihistaminic norastemizole
87. The high-pressure S(N)AR reaction of N-p-fluorobenzyl-2-chlorobenzimidazole with amines; An approach to norastemizole and analogues
88. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole
89. The erg-like potassium current in rat lactotrophs
90. Quantitation of efletirizine in human plasma and urine using automated solid-phase extraction and column-switching high-performance liquid chromatography
91. 1-receptor antagonists, and why it matters
92. Remarkably selective palladium-catalyzed amination process: Rapid assembly of multiamino based structures
93. 2+ influx
94. Norastemizole. Antihistamine
95. 1-antihistaminika
96. Cardiotoxic effects of astemizole overdose in children
97. Risk of selected serious cardiac events among new users of antihistamines
98. Receptor binding properties of astemizole and its metabolite norastemizole
99. The effects of astemizole and norstemizole on cardiovascular responses in conscious dogs
100. Possible interactions with terfenadine or astemizole
101. Pharmacokinetics and pharmacodynamics of norstemizole in normal volunteers
102. Norastemizole does not affect ECG parameters
103. QT lengthening and life-threatening arrhythmias associated with fexofenadine
104. QT lengthening and arrhythmias associated with fexofenadine
105. Authors' reply
106. Sepracor